HIV disease management: New technologies improve outcomes and contain costs

AIDS Reader

Volumn 12, Issue 2, 2002, Pages 64-66

  Valenti, William M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cost containment; Resistance testing; Viral load testing

Indexed keywords

VIRUS RNA;

ANTIBIOTIC RESISTANCE; CHRONIC DISEASE; COST CONTROL; DIAGNOSTIC TEST; EPIDEMIC; HEALTH CARE COST; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MANAGED CARE ORGANIZATION; MEDICAL TECHNOLOGY; MORBIDITY; PATIENT CARE; SHORT SURVEY; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COST CONTROL; DISEASE MANAGEMENT; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0036194084     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Variation and changes in expenditures for HIV care among American adults in the era of highly active therapy
2. Actual costs of HIV/AIDS care
3. HAART-related cost savings from decreased utilization of diagnostic microbiology lab
4. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs
5. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy
6. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
7. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART: The Viradaptstudy, week 48 follow-up
8. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
9. Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA3001)
10. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
11. Utility of HIV genotyping and clinical expert advice
12. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
13. HIV-1 drug resistance in newly infected individuals